379 related articles for article (PubMed ID: 20028264)
1. Hyperemia-associated costs of medication changes in glaucoma patients treated initially with prostaglandin analogs.
Schwartz GF; Tan J; Kotak S
J Ocul Pharmacol Ther; 2009 Dec; 25(6):555-61. PubMed ID: 20028264
[TBL] [Abstract][Full Text] [Related]
2. Ocular surface tolerability of prostaglandin analogs in patients with glaucoma or ocular hypertension.
Whitson JT; Trattler WB; Matossian C; Williams J; Hollander DA
J Ocul Pharmacol Ther; 2010 Jun; 26(3):287-92. PubMed ID: 20578283
[TBL] [Abstract][Full Text] [Related]
3. Cost-offset analysis: bimatoprost versus other prostaglandin analogues in open-angle glaucoma.
Berenson KL; Kymes S; Hollander DA; Fiscella R; Burk C; Patel VD
Am J Manag Care; 2011 Sep; 17(9):e365-74. PubMed ID: 21902444
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of monotherapy treatment of glaucoma and ocular hypertension with the lipid class of medications.
Noecker RJ; Walt JG
Am J Ophthalmol; 2006 Jan; 141(1 Suppl):S15-21. PubMed ID: 16389056
[TBL] [Abstract][Full Text] [Related]
5. Refill rates and budget impact of glaucoma lipid therapy: a retrospective database analysis.
Walt JG; Wilensky JT; Fiscella R; Chiang TH; Guckian A
Clin Drug Investig; 2007; 27(12):819-25. PubMed ID: 18020539
[TBL] [Abstract][Full Text] [Related]
6. Physicians' treatment decisions, patient persistence, and interruptions in the continuous use of prostaglandin therapy in glaucoma.
Hahn SR; Kotak S; Tan J; Kim E
Curr Med Res Opin; 2010 Apr; 26(4):957-63. PubMed ID: 20163296
[TBL] [Abstract][Full Text] [Related]
7. Ocular surface tolerability of prostaglandin analogs and prostamides in patients with glaucoma or ocular hypertension.
Crichton AC; Vold S; Williams JM; Hollander DA
Adv Ther; 2013 Mar; 30(3):260-70. PubMed ID: 23475405
[TBL] [Abstract][Full Text] [Related]
8. Conjunctival hyperaemia with the use of latanoprost versus other prostaglandin analogues in patients with ocular hypertension or glaucoma: a meta-analysis of randomised clinical trials.
Honrubia F; García-Sánchez J; Polo V; de la Casa JM; Soto J
Br J Ophthalmol; 2009 Mar; 93(3):316-21. PubMed ID: 19019922
[TBL] [Abstract][Full Text] [Related]
9. Long-term medical management of primary open-angle glaucoma and ocular hypertension in the UK: optimizing cost-effectiveness and clinic resources by minimizing therapy switches.
Orme M; Collins S; Loftus J
J Glaucoma; 2012 Sep; 21(7):433-49. PubMed ID: 21677590
[TBL] [Abstract][Full Text] [Related]
10. A cost-effectiveness analysis of fixed-combination therapies in patients with open-angle glaucoma: a European perspective.
Hommer A; Wickstrøm J; Friis MM; Steeds C; Thygesen J; Ferreras A; Gouws P; Buchholz P
Curr Med Res Opin; 2008 Apr; 24(4):1057-63. PubMed ID: 18315942
[TBL] [Abstract][Full Text] [Related]
11. Hyperemia reduction after administration of a fixed combination of bimatoprost and timolol maleate to patients on prostaglandin or prostamide monotherapy.
Paranhos A; Mendonça M; Silva MJ; Giampani J; Torres RJ; Della Paolera M; Russ H; Lottenberg CL
J Ocul Pharmacol Ther; 2010 Dec; 26(6):611-5. PubMed ID: 21029020
[TBL] [Abstract][Full Text] [Related]
12. Pharmacoeconomic analysis of prostaglandin and prostamide therapy for patients with glaucoma or ocular hypertension.
Frenkel RE; Frenkel M; Toler A
BMC Ophthalmol; 2007 Sep; 7():16. PubMed ID: 17900371
[TBL] [Abstract][Full Text] [Related]
13. First-year treatment patterns among new initiators of topical prostaglandin analogs.
Schmier JK; Covert DW; Robin AL
Curr Med Res Opin; 2009 Apr; 25(4):851-8. PubMed ID: 19231912
[TBL] [Abstract][Full Text] [Related]
14. Patient persistency with ocular prostaglandin therapy: a population-based, retrospective study.
Reardon G; Schwartz GF; Mozaffari E
Clin Ther; 2003 Apr; 25(4):1172-85. PubMed ID: 12809964
[TBL] [Abstract][Full Text] [Related]
15. Comparative efficacy and tolerability of topical prostaglandin analogues for primary open-angle glaucoma and ocular hypertension.
Lin L; Zhao YJ; Chew PT; Sng CC; Wong HT; Yip LW; Wu TS; Bautista D; Teng M; Khoo AL; Lim BP
Ann Pharmacother; 2014 Dec; 48(12):1585-93. PubMed ID: 25184309
[TBL] [Abstract][Full Text] [Related]
16. Assessment of the cost effectiveness of travoprost versus latanoprost as single agents for treatment of glaucoma in France.
Payet S; Denis P; Berdeaux G; Launois R
Clin Drug Investig; 2008; 28(3):183-98. PubMed ID: 18266403
[TBL] [Abstract][Full Text] [Related]
17. Adjunctive glaucoma therapy use associated with travoprost, bimatoprost, and latanoprost.
Covert D; Robin AL
Curr Med Res Opin; 2006 May; 22(5):971-6. PubMed ID: 16709319
[TBL] [Abstract][Full Text] [Related]
18. [The more favourable cost/effectiveness ratio of latanoprost vs bimatoprost and travoprost when using normally for treatment of glaucoma].
Soto J
Arch Soc Esp Oftalmol; 2005 Jan; 80(1):9-10; author reply 10. PubMed ID: 15692888
[No Abstract] [Full Text] [Related]
19. The impact of ocular adverse effects in patients treated with topical prostaglandin analogs: changes in prescription patterns and patient persistence.
Zimmerman TJ; Hahn SR; Gelb L; Tan H; Kim EE
J Ocul Pharmacol Ther; 2009 Apr; 25(2):145-52. PubMed ID: 19284321
[TBL] [Abstract][Full Text] [Related]
20. Blood-aqueous barrier changes after the use of prostaglandin analogues in patients with pseudophakia and aphakia: a 6-month randomized trial.
Arcieri ES; Santana A; Rocha FN; Guapo GL; Costa VP
Arch Ophthalmol; 2005 Feb; 123(2):186-92. PubMed ID: 15710814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
